Strategies for management of inflammatory bowel diseases are shifting from simple control
of symptoms toward full control of these diseases (clinical and endoscopic remission), with …

Leukocyte trafficking to the small and large intestines is tightly controlled to maintain
intestinal immune homeostasis, mediate immune responses, and regulate inflammation. A …

Celiac disease has become one of the best-understood HLA-linked disorders. Although it
shares many immunologic features with inflammatory bowel disease, celiac disease is …

The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have
been the receptors CCR9 and CXCR3 and their respective ligands CCL25 and CXCL10 …

T lymphocytes play a central role in regulation of the immune system. Both effector and
regulatory T cells work in equilibrium to provide optimal immune response against foreign …

Crohn's disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current
biologic therapies are limited to blocking tumor necrosis factor alpha. However, some …

Background A high proportion of patients with inflammatory bowel disease (IBD) do not
achieve clinical remission with the current therapies including mesalazine (mesalamine) …

Chemokine is a structure-related protein with a relatively small molecular weight, which can
target cells to chemotaxis and promote inflammatory response. Inflammation plays an …

The SAMP1/YitFc mouse strain represents a model of Crohn's disease (CD)-like ileitis that is
ideal for investigating the pathogenesis of chronic intestinal inflammation. Different from the …

Inflammatory bowel diseases (IBD) are a complex group of diseases involving alterations in
mucosal immunity and gastrointestinal physiology during both initiation and progressive …